What company developed the new technology for controlling the pore diameter of PMMA porous fibers?

Toray Industries, Inc., which is headquartered in Chuo-ku, Tokyo, developed this new technology.

What range of pore diameters can be arbitrarily controlled using Toray's newly developed technology?

The technology can control the pore diameter in a wide range from several nanometers to about 1,000 nm.

Which diseases could benefit from the new blood purification treatment options proposed by Toray?

It proposed options for intractable diseases like autoimmune, cardiovascular metabolic, and neurodegenerative diseases.

What kinds of large-molecular-weight pathogenic substances in the blood is there a growing demand to remove?

There is a growing demand to efficiently remove substances such as autoantibodies, lipoproteins, and exosomes.

What technologies did Toray combine to develop their pore size control technology?

Toray combined advanced analytical technologies like small-angle X-ray scattering and digital phase separation simulations.

AI News NQ Analysis

Creation of Porous Fibers That Adsorb Pathogenic Substances of Intractable Diseases

NQ Score 50/100

Key facts

Creation of Porous Fibers That Adsorb Pathogenic Substances of Intractable Diseases
Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.
Source: PR TIMES
Date: Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)

Direct answer

Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.

Citation: Creation of Porous Fibers That Adsorb Pathogenic Substances of Intractable Diseases (Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Sat Mar 28 2026 00:08:15 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers over a wide range, from several nanometers to about 1,000 nm. This has led to the creation of porous fibers that can selectively adsorb pathogenic substances related to intractable diseases. This technology offers a new option for blood purification therapy for conditions like autoimmune diseases, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer, which can be an alternative or a complement to conventional treatments.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What company developed the new technology for controlling the pore diameter of PMMA porous fibers?: A: Toray Industries, Inc., which is headquartered in Chuo-ku, Tokyo, developed this new technology.
Q: What range of pore diameters can be arbitrarily controlled using Toray's newly developed technology?: A: The technology can control the pore diameter in a wide range from several nanometers to about 1,000 nm.
Q: Which diseases could benefit from the new blood purification treatment options proposed by Toray?: A: It proposed options for intractable diseases like autoimmune, cardiovascular metabolic, and neurodegenerative diseases.
Q: What kinds of large-molecular-weight pathogenic substances in the blood is there a growing demand to remove?: A: There is a growing demand to efficiently remove substances such as autoantibodies, lipoproteins, and exosomes.
Q: What technologies did Toray combine to develop their pore size control technology?: A: Toray combined advanced analytical technologies like small-angle X-ray scattering and digital phase separation simulations.